Faruqi & Faruqi Urges Investors of Applied Therapeutics to Act Ahead of Class Action Deadline
Faruqi & Faruqi, LLP, a prominent national securities law firm, has announced its ongoing investigation into Applied Therapeutics, Inc. for potential claims in light of a federal securities class action lawsuit. The firm is urging investors who have incurred losses exceeding $50,000 due to their investments in Applied Therapeutics between January and December 2024, to take immediate action before the deadline on February 18, 2025. This situation arises from the allegations that the company and its executives made misleading statements and failed to disclose critical information about their Phase III INSPIRE trial, leading to inflated stock prices. These claims follow a significant downturn in the company's stock after it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application for govorestat, a treatment for Classic Galactosemia.
The CRL issued on November 27, 2024, indicated substantial deficiencies in the clinical data presented by the company, particularly around issues in their electronic data capture methods. This triggered a sharp decline in stock value, signaling to investors that the assertions made by the company could have been misleading. Subsequently, another hit to the company's reputation came on December 3, 2024, when the FDA published a warning letter stating that Applied Therapeutics had been aware of significant issues in its NDA since May 2024. Following these events, investors experienced a dramatic drop in stock value, raising concerns about their financial situation, and highlighting the importance of taking legal action against the company to seek restitution for their losses.
Faruqi & Faruqi's partner, Josh Wilson, is actively reaching out to affected investors, encouraging them to discuss their rights and possible legal strategies. Investors can contact him directly via phone to learn about their options and determine whether they qualify for leading the class action suit. It is crucial for potential plaintiffs to understand the process of serving in a lead plaintiff role, which involves directing and overseeing litigation on behalf of all affected shareholders.
If you believe you have been a victim of misleading corporate conduct by Applied Therapeutics, this is a vital opportunity to advocate for your rights. Your participation in the class action not only provides a channel for seeking financial compensation but also holds the company accountable for their allegations of misconduct. Furqan & Faruqi encourages anyone with information regarding Applied Therapeutics' actions, including former employees and whistleblowers, to come forward, as every piece of information may be crucial in building a compelling case for the class action.
In conclusion, the upcoming deadline presents a crucial opportunity for investors to step forward regarding their losses and grievances against Applied Therapeutics. A fair and thorough examination of the circumstances surrounding the company’s disclosures is paramount in ensuring justice is served. By staying informed and proactive, investors can ensure their voices are heard in this significant legal matter.
The CRL issued on November 27, 2024, indicated substantial deficiencies in the clinical data presented by the company, particularly around issues in their electronic data capture methods. This triggered a sharp decline in stock value, signaling to investors that the assertions made by the company could have been misleading. Subsequently, another hit to the company's reputation came on December 3, 2024, when the FDA published a warning letter stating that Applied Therapeutics had been aware of significant issues in its NDA since May 2024. Following these events, investors experienced a dramatic drop in stock value, raising concerns about their financial situation, and highlighting the importance of taking legal action against the company to seek restitution for their losses.
Faruqi & Faruqi's partner, Josh Wilson, is actively reaching out to affected investors, encouraging them to discuss their rights and possible legal strategies. Investors can contact him directly via phone to learn about their options and determine whether they qualify for leading the class action suit. It is crucial for potential plaintiffs to understand the process of serving in a lead plaintiff role, which involves directing and overseeing litigation on behalf of all affected shareholders.
If you believe you have been a victim of misleading corporate conduct by Applied Therapeutics, this is a vital opportunity to advocate for your rights. Your participation in the class action not only provides a channel for seeking financial compensation but also holds the company accountable for their allegations of misconduct. Furqan & Faruqi encourages anyone with information regarding Applied Therapeutics' actions, including former employees and whistleblowers, to come forward, as every piece of information may be crucial in building a compelling case for the class action.
In conclusion, the upcoming deadline presents a crucial opportunity for investors to step forward regarding their losses and grievances against Applied Therapeutics. A fair and thorough examination of the circumstances surrounding the company’s disclosures is paramount in ensuring justice is served. By staying informed and proactive, investors can ensure their voices are heard in this significant legal matter.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.